Laparoscopically assisted ilio-inguinal lymph node dissection versus inguinal lymph node dissection in melanoma.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2020-07-21 DOI:10.2217/mmt-2019-0023

Enrique Boldo, Araceli Mayol, Rafael Lozoya, Alba Coret, Diana Escribano, Carlos Fortea, Andres Muñoz, Juan Carlos Pastor, Guillermo Perez De Lucia

{"title":"Laparoscopically assisted ilio-inguinal lymph node dissection versus inguinal lymph node dissection in melanoma.","authors":"Enrique Boldo, Araceli Mayol, Rafael Lozoya, Alba Coret, Diana Escribano, Carlos Fortea, Andres Muñoz, Juan Carlos Pastor, Guillermo Perez De Lucia","doi":"10.2217/mmt-2019-0023","DOIUrl":null,"url":null,"abstract":"Aim: Morbidity of open inguinal lymphadenectomy (OIL) is high. We use laparoscopy for pelvic time, preservation of the greater saphenous vein and transverse inguinal incisions (laparoscopically assisted ilio-inguinal lymphadenectomy, LIIL) to improve postoperative outcomes.Patients & methods: Retrospective comparison of 14 patients who underwent LIIL and seven patients who underwent OIL.Results: Fourteen LIIL compared with seven OIL showed a statistically significant reduction in morbidity (15.3 vs 75%) and hospital stay (7 vs 15.7 days). Pelvic lymph node involvement (27%) was not detected preoperatively. With a mean follow-up of 36.2 (range: 3-137) months, local recurrence rate was 58.3% in LIIL and 40% in OIL. Overall survival was significantly higher in OIL than in LIIL.Conclusion: Compared with OIL, LIIL reduced postoperative complications and hospital stay.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2020-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2019-0023","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2019-0023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Aim: Morbidity of open inguinal lymphadenectomy (OIL) is high. We use laparoscopy for pelvic time, preservation of the greater saphenous vein and transverse inguinal incisions (laparoscopically assisted ilio-inguinal lymphadenectomy, LIIL) to improve postoperative outcomes.

Patients & methods: Retrospective comparison of 14 patients who underwent LIIL and seven patients who underwent OIL.

Results: Fourteen LIIL compared with seven OIL showed a statistically significant reduction in morbidity (15.3 vs 75%) and hospital stay (7 vs 15.7 days). Pelvic lymph node involvement (27%) was not detected preoperatively. With a mean follow-up of 36.2 (range: 3-137) months, local recurrence rate was 58.3% in LIIL and 40% in OIL. Overall survival was significantly higher in OIL than in LIIL.

Conclusion: Compared with OIL, LIIL reduced postoperative complications and hospital stay.

Abstract Image

查看原文本刊更多论文

腹腔镜辅助髂-腹股沟淋巴结清扫与黑色素瘤腹股沟淋巴结清扫。

目的:开放式腹股沟淋巴结切除术(OIL)的发病率高。我们使用腹腔镜检查盆腔时间，保留大隐静脉和腹股沟横切口(腹腔镜辅助髂-腹股沟淋巴结切除术，LIIL)来改善术后预后。患者与方法:回顾性比较14例LIIL患者和7例OIL患者。结果:14例LIIL与7例OIL相比，发病率(15.3 vs 75%)和住院时间(7 vs 15.7天)有统计学意义。术前未发现盆腔淋巴结受累(27%)。平均随访36.2个月(范围:3-137个月)，LIIL和OIL的局部复发率分别为58.3%和40%。OIL患者的总生存率明显高于LIIL患者。结论:与OIL相比，LIIL减少了术后并发症和住院时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.